Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma

Affiliation auteurs!!!! Error affiliation !!!!
TitrePretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
Type de publicationJournal Article
Year of Publication2014
AuteursSasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas R-O, Biggi A, Gallamini A, Siegel BA, Cashen AF, Vera P, Tilly H, Versari A, Itti E
JournalEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume41
Pagination2017-2022
Date PublishedNOV
Type of ArticleArticle
ISSN1619-7070
Mots-clésdiffuse large B-cell lymphoma, Metabolic tumour volume, Outcome prediction, PET/CT, Total lesion glycolysis
Résumé

{Purpose We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL). Methods TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent F-18-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41% using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). Results Median follow-up was 39 months. Average pretherapy TMTV was 509 +/- 568 cm(3). The 3-year estimates of PFS were 77% in the low metabolic burden group (TMTV <= 550 cm(3)) and 60% in the high metabolic burden group (TMTV >550 cm(3)
DOI10.1007/s00259-014-2822-7